GR20100100333A - Morpholine derivatives of substituted diphenyl compounds - Google Patents

Morpholine derivatives of substituted diphenyl compounds

Info

Publication number
GR20100100333A
GR20100100333A GR20100100333A GR20100100333A GR20100100333A GR 20100100333 A GR20100100333 A GR 20100100333A GR 20100100333 A GR20100100333 A GR 20100100333A GR 20100100333 A GR20100100333 A GR 20100100333A GR 20100100333 A GR20100100333 A GR 20100100333A
Authority
GR
Greece
Prior art keywords
dyslipidemia
morpholine derivatives
disease
compounds
diphenyl compounds
Prior art date
Application number
GR20100100333A
Other languages
Greek (el)
Inventor
Αγγελικη Παναγιωτη Κουρουνακη
Original Assignee
Αγγελικη Παναγιωτη Κουρουνακη
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Αγγελικη Παναγιωτη Κουρουνακη filed Critical Αγγελικη Παναγιωτη Κουρουνακη
Priority to GR20100100333A priority Critical patent/GR20100100333A/en
Publication of GR20100100333A publication Critical patent/GR20100100333A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to morpholine derivatives of hydroxylated diphenyl compounds, processes for preparing them and pharmaceutical preparations containing them. The morpholine derivatives of hydroxylated diphenyl compounds of this invention exhibit enhanced antioxidant, lipid lowering and anti-inflammatory action and can be used for the prevention and treatment of diseases associated with oxidative stress, inflammation or dyslipidemia, or any combination of these phenomena. More specifically, the compounds of the present invention are useful for the treatment and prevention of a disease condition related to dyslipidemia, oxidative stress, inflammation or a combination thereof, such as atherosclerosis, diabetes, obesity, dyslipidemia, rheumatoid arthritis, Alzheimer`s disease, asthma, Parkinson`s disease, stroke, arrhythmias, hypertension, ischemia, hart failure, thromboembolism, atopic dermatitis, psoriasis, eczema, renitis, colitis, cancer, ulcer, Lupus erythematosus, multiple sclerosis, depression, schizophrenia, infective diseases and septic shock.
GR20100100333A 2010-06-10 2010-06-10 Morpholine derivatives of substituted diphenyl compounds GR20100100333A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20100100333A GR20100100333A (en) 2010-06-10 2010-06-10 Morpholine derivatives of substituted diphenyl compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20100100333A GR20100100333A (en) 2010-06-10 2010-06-10 Morpholine derivatives of substituted diphenyl compounds

Publications (1)

Publication Number Publication Date
GR20100100333A true GR20100100333A (en) 2012-01-31

Family

ID=43528402

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20100100333A GR20100100333A (en) 2010-06-10 2010-06-10 Morpholine derivatives of substituted diphenyl compounds

Country Status (1)

Country Link
GR (1) GR20100100333A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042030A1 (en) * 1999-01-14 2000-07-20 Elpen S.A. Hypolipidemic and antioxidant morpholine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042030A1 (en) * 1999-01-14 2000-07-20 Elpen S.A. Hypolipidemic and antioxidant morpholine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROY, K. ET AL., CHEM BIOL DRUG DES, vol. 74, 2009, pages 507 - 516, XP002620499 *

Similar Documents

Publication Publication Date Title
BR112014030202A2 (en) microorganisms and methods for the production of 4-hydroxybutyrate 1,4-butanediol and related compounds
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
MY185837A (en) Heteroaryl syk inhibitors
NZ600449A (en) Compound suitable for the treatment of synucleopathies
WO2011150156A3 (en) Heteroaryl compounds and methods of use thereof
MX2019007373A (en) Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors.
MX2015013042A (en) Organic compounds.
EP3303594A4 (en) Genetically engineered microorganisms for the production of chorismate-derived products
EP3016527A4 (en) Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella
WO2010085072A3 (en) Divided wall distillation column for producing high purity normal butanol, and normal butanol distillation method
MX2011009369A (en) Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators.
EP3788136A4 (en) Engineered microorganism for the production of cannabinoid biosynthetic pathway products
UA108858C2 (en) ISOXALIDINE DERIVATIVES
WO2016094878A8 (en) Methods for converting cellulose to furanic products
MX2011008825A (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators.
EP3824044C0 (en) Production of hydrocarbons from recycled or renewable organic material
MX2017007377A (en) Organic compounds.
MX360957B (en) Process of making adamantanamides.
MY170826A (en) Highly aromatic base oil and method for producing highly aromatic base oil
MX2011009338A (en) Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators.
FR3016360B1 (en) PROCESS FOR THE PREPARATION OF A METAL OXIDE POWDER, PROCESS FOR PRODUCING A METAL OXIDE PASTILLE, AND USES OF POWDER AND PASTILLE AS EXTENDED THEREFROM
EP3257934A4 (en) New dibasic organic acid producing strain and preparation and application of same
NZ702239A (en) Heteroaryl compounds and methods of use thereof
GR20100100333A (en) Morpholine derivatives of substituted diphenyl compounds
MX2016012851A (en) A method to produce 1,1,2,3-tetrachloropropene with high yield.

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20130104